ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date
  • Abstract Number: 825

    Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study
  • Abstract Number: 826

    Does Anti-Glomerular Basement (anti-GBM) Antibody Positivity Correlate with Relapse in Patients with Anti-GBM Disease?
  • Abstract Number: 827

    Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
  • Abstract Number: 828

    Medium and Small-Sized Vessel Involvement in Hypereosinophilic Syndrome
  • Abstract Number: 829

    DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs
  • Abstract Number: 830

    Primary Central Nervous System Vasculitis with Tumor-like Presentation
  • Abstract Number: 831

    No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response
  • Abstract Number: 832

    Immunoglobuline a Vasculitis: Comparison between Pediatric and Adult Population
  • Abstract Number: 833

    11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK
  • Abstract Number: 834

    Clinical Characteristics of IgA Vasculitis in Children and Adults: A Retrospective Cohort Study
  • Abstract Number: 835

    WITHDRAWN
  • Abstract Number: 836

    Genetic Risk Score Prediction in Ankylosing Spondylitis
  • Abstract Number: 837

    Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Seropositive Rheumatoid Arthritis Patients
  • Abstract Number: 838

    Efficacy and Safety of Combined Immunosuppressive Therapy with High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Disease Accompanied By Anti-MDA5-Positive Dermatomyositis -a Multicenter Prospective Study –
  • Abstract Number: 839

    Fibromyalgia Is Identified in Routine Care on Indices Derived from an MDHAQ (MultiDimensional Health Assessment Questionnaire) with Robust Agreement with 2011 Revised Fibromyalgia Criteria Questionnaire
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 202
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology